Rocket Pharmaceuticals, Inc. Number of Operating Segments
Rocket Pharmaceuticals, Inc. (RCKT) reported Number of Operating Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. number of operating segments for the quarter ending 2026-03-31 was 1.00 Segment.
- Rocket Pharmaceuticals, Inc. number of operating segments for the quarter ending 2018-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. number of operating segments for the quarter ending 2017-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. number of operating segments for the quarter ending 2016-03-31 was 1.00 Segment.
- Rocket Pharmaceuticals, Inc. number of operating segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Rocket Pharmaceuticals, Inc. number of operating segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- Rocket Pharmaceuticals, Inc. number of operating segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- Rocket Pharmaceuticals, Inc. number of operating segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-02-27 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-03-06 | |||
| 2018-12-31 | 1.00 Segment 10-K · filed 2019-03-08 | |||
| 2018-09-30 | 1.00 Segment 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | 1.00 Segment 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 1.00 Segment 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | 1.00 Segment 10-K · filed 2018-03-07 | |||
| 2017-09-30 | 1.00 Segment 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | 1.00 Segment 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | 1.00 Segment 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | 1.00 Segment 10-K · filed 2017-03-16 | |||
| 2016-09-30 | 1.00 Segment 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | 1.00 Segment 10-Q · filed 2016-08-10 | |||
| 2016-03-31 | 1.00 Segment 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | 1.00 Segment 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |